Meenta, Inc announced a partnership with Agilent technologies today (17th Feb 2022). The goal of the partnership is to help researches get access to better sequencing technologies, faster and cheaper.
“The partnership will provide a unified way to access laboratory reagents, instruments, and informatics resulting in a faster and more efficient road to data which then can, in turn, be translated into foundational discoveries that can change lives,”
Gabor Bethlendy, CEO, Meenta, Inc.
Meenta act as a market place to aggregate demand and reduce the cost of consumables whilst also allowing easy comparison of options, all with fully transparent pricing. The company is essentially giving researchers access to top of the range sequencing labs, where they can get access to data faster and ultimately gather insights in clinical discoveries to help patients.
The deal that was announce today is showing that Agilent are bringing their SureSelect exome kits and other panels into the platform, the goal here is to give researches access to Agilent’s targeted sequencing offerings
About Meenta
Meenta was born out of the idea that life science and diagnostics could greatly benefit from the technological revolution that has forever changed the way we shop, dine, vacation, and catch a ride. Grounded in technology and sitting at the intersection of supply and demand, the Meenta marketplace brings together the widest array of testing products and laboratory services.